Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075128 | 0.92 | TLR9 (0.35) | ACHEHRH3OPRK1TLR9TLR8 | |
| SCHEMBL25075312 | 0.92 | TLR9 (0.35) | ACHEHRH3OPRK1TLR9TLR8 | |
| SCHEMBL25075152 | 0.90 | ACHE (0.34) | ACHEOPRK1 | |
| SCHEMBL25074999 | 0.84 | HRH3 (0.36) | ACHEHRH3TLR9TLR8TLR7 | |
| SCHEMBL25075150 | 0.83 | ACHE (0.33) | ACHEOPRK1 | |
| SCHEMBL14453788 | 0.81 | HRH3 (0.37) | HRH3OPRK1 | |
| SCHEMBL18327495 | 0.81 | HRH3 (0.37) | HRH3OPRK1 | |
| SCHEMBL102379 | 0.81 | HRH3 (0.42) | HRH3OPRK1 | |
| SCHEMBL25075002 | 0.81 | ACHE (0.39) | ACHEHRH3OPRK1TLR9TLR8 | |
| SCHEMBL25466871 | 0.80 | ACHE (0.41) | ACHEHRH3OPRK1TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | ACHE 3459/4885HRH3 3222/4885OPRK1 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.